Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast

Local recurrence is used as a marker of treatment failure for patients with ductal carcinoma in situ (DCIS). As follow-up lengthens, distant recurrence, breast cancer–specific survival (BCSS), and overall survival must be monitored. A prospective database was used to analyze 1031 patients with DCIS....

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2004-10, Vol.188 (4), p.371-376
Main Authors: Romero, Lina, Klein, Laura, Ye, Wei, Holmes, Dennis, Soni, Rashida, Silberman, Howard, Lagios, Michael D., Silverstein, Melvin J.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Breast cancer
Breast cancer–specific survival
Breast Neoplasms - mortality
Cancer therapies
Carcinoma in Situ - mortality
Carcinoma, Ductal, Breast - mortality
Ductal carcinoma in situ
Fatalities
Female
Follow-Up Studies
General aspects
Gynecology. Andrology. Obstetrics
Humans
Invasive recurrence
Local recurrence
Mammary gland diseases
Mammography
Medical research
Medical sciences
Mortality
Neoplasm Invasiveness
Neoplasm Recurrence, Local - mortality
Probability
Prospective Studies
Radiation therapy
Survival Rate
Therapy
Time Factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c447t-8e6bd78d477ace63f77164ee4cce1cdada91ab4dafff3865d14e046b75e6f6173
cites cdi_FETCH-LOGICAL-c447t-8e6bd78d477ace63f77164ee4cce1cdada91ab4dafff3865d14e046b75e6f6173
container_end_page 376
container_issue 4
container_start_page 371
container_title The American journal of surgery
container_volume 188
creator Romero, Lina
Klein, Laura
Ye, Wei
Holmes, Dennis
Soni, Rashida
Silberman, Howard
Lagios, Michael D.
Silverstein, Melvin J.
description Local recurrence is used as a marker of treatment failure for patients with ductal carcinoma in situ (DCIS). As follow-up lengthens, distant recurrence, breast cancer–specific survival (BCSS), and overall survival must be monitored. A prospective database was used to analyze 1031 patients with DCIS. Patients having invasive recurrence after DCIS treatment were compared with patients having infiltrating ductal carcinoma (IDC). End points included distant recurrence, BCSS, and overall survival. Overall, patients with DCIS had a BCSS of 99%. BCSS was 85% for patients with invasive recurrences. DDFS in this group was 80%. Stage I IDC patients had a BCSS of 91%, whereas it was 38% in those with stage I IDC and invasive recurrences. Most patients with DCIS that recur can be salvaged. For the small subgroup of patients who recur with invasive breast cancer, survival is similar to that of patients with stage IIA IDC.
doi_str_mv 10.1016/j.amjsurg.2004.06.034
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66944975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961004003095</els_id><sourcerecordid>3107829531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-8e6bd78d477ace63f77164ee4cce1cdada91ab4dafff3865d14e046b75e6f6173</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7jj6E5SA6K3HVHc6SZ9kWfyChb3owVNIJxU3TX-MSXrEf2-GaVjwoKeiiqeK4n0IeQnsAAzEu-FgpiGt8cehZowfmDiwhj8iO1Cyq0Cp5jHZMcbqqhPArsizlIbSAvDmKbmClkvOa7Uj3-_WbJcJqfEZIw3zyaRwQhrRrjHibLHM6NHkgHNO9FfI99StNpuRWhNtmJfJnIkU8koXT_M90j6iSfk5eeLNmPDFVvfk28cPX28-V7d3n77cXN9WlnOZK4Wid1I5LqWxKBovJQiOyK1FsM4404HpuTPe-0aJ1gFHxkUvWxRegGz25O3l7jEuP1dMWU8hWRxHM-OyJi1Ex3kn2wK-_gscljXO5TcNnHNRK-DynxRroGbASrh70l4oG5eUInp9jGEy8XeB9NmPHvTmR5_9aCZ08VP2Xm3X135C97C1CSnAmw0wyZrRRzPbkB44AQpAicK9v3BYoj0FjDrZcNblQlGXtVvCf175A86UsQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1031201088</pqid></control><display><type>article</type><title>Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast</title><source>ScienceDirect Freedom Collection</source><creator>Romero, Lina ; Klein, Laura ; Ye, Wei ; Holmes, Dennis ; Soni, Rashida ; Silberman, Howard ; Lagios, Michael D. ; Silverstein, Melvin J.</creator><creatorcontrib>Romero, Lina ; Klein, Laura ; Ye, Wei ; Holmes, Dennis ; Soni, Rashida ; Silberman, Howard ; Lagios, Michael D. ; Silverstein, Melvin J.</creatorcontrib><description>Local recurrence is used as a marker of treatment failure for patients with ductal carcinoma in situ (DCIS). As follow-up lengthens, distant recurrence, breast cancer–specific survival (BCSS), and overall survival must be monitored. A prospective database was used to analyze 1031 patients with DCIS. Patients having invasive recurrence after DCIS treatment were compared with patients having infiltrating ductal carcinoma (IDC). End points included distant recurrence, BCSS, and overall survival. Overall, patients with DCIS had a BCSS of 99%. BCSS was 85% for patients with invasive recurrences. DDFS in this group was 80%. Stage I IDC patients had a BCSS of 91%, whereas it was 38% in those with stage I IDC and invasive recurrences. Most patients with DCIS that recur can be salvaged. For the small subgroup of patients who recur with invasive breast cancer, survival is similar to that of patients with stage IIA IDC.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2004.06.034</identifier><identifier>PMID: 15474428</identifier><identifier>CODEN: AJSUAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Biological and medical sciences ; Breast cancer ; Breast cancer–specific survival ; Breast Neoplasms - mortality ; Cancer therapies ; Carcinoma in Situ - mortality ; Carcinoma, Ductal, Breast - mortality ; Ductal carcinoma in situ ; Fatalities ; Female ; Follow-Up Studies ; General aspects ; Gynecology. Andrology. Obstetrics ; Humans ; Invasive recurrence ; Local recurrence ; Mammary gland diseases ; Mammography ; Medical research ; Medical sciences ; Mortality ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local - mortality ; Probability ; Prospective Studies ; Radiation therapy ; Survival Rate ; Therapy ; Time Factors ; Tumors</subject><ispartof>The American journal of surgery, 2004-10, Vol.188 (4), p.371-376</ispartof><rights>2004 Excerpta Medica Inc.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Oct 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-8e6bd78d477ace63f77164ee4cce1cdada91ab4dafff3865d14e046b75e6f6173</citedby><cites>FETCH-LOGICAL-c447t-8e6bd78d477ace63f77164ee4cce1cdada91ab4dafff3865d14e046b75e6f6173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27900,27901</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16181186$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15474428$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romero, Lina</creatorcontrib><creatorcontrib>Klein, Laura</creatorcontrib><creatorcontrib>Ye, Wei</creatorcontrib><creatorcontrib>Holmes, Dennis</creatorcontrib><creatorcontrib>Soni, Rashida</creatorcontrib><creatorcontrib>Silberman, Howard</creatorcontrib><creatorcontrib>Lagios, Michael D.</creatorcontrib><creatorcontrib>Silverstein, Melvin J.</creatorcontrib><title>Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Local recurrence is used as a marker of treatment failure for patients with ductal carcinoma in situ (DCIS). As follow-up lengthens, distant recurrence, breast cancer–specific survival (BCSS), and overall survival must be monitored. A prospective database was used to analyze 1031 patients with DCIS. Patients having invasive recurrence after DCIS treatment were compared with patients having infiltrating ductal carcinoma (IDC). End points included distant recurrence, BCSS, and overall survival. Overall, patients with DCIS had a BCSS of 99%. BCSS was 85% for patients with invasive recurrences. DDFS in this group was 80%. Stage I IDC patients had a BCSS of 91%, whereas it was 38% in those with stage I IDC and invasive recurrences. Most patients with DCIS that recur can be salvaged. For the small subgroup of patients who recur with invasive breast cancer, survival is similar to that of patients with stage IIA IDC.</description><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast cancer–specific survival</subject><subject>Breast Neoplasms - mortality</subject><subject>Cancer therapies</subject><subject>Carcinoma in Situ - mortality</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Ductal carcinoma in situ</subject><subject>Fatalities</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Invasive recurrence</subject><subject>Local recurrence</subject><subject>Mammary gland diseases</subject><subject>Mammography</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Probability</subject><subject>Prospective Studies</subject><subject>Radiation therapy</subject><subject>Survival Rate</subject><subject>Therapy</subject><subject>Time Factors</subject><subject>Tumors</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkU2LFDEQhoMo7jj6E5SA6K3HVHc6SZ9kWfyChb3owVNIJxU3TX-MSXrEf2-GaVjwoKeiiqeK4n0IeQnsAAzEu-FgpiGt8cehZowfmDiwhj8iO1Cyq0Cp5jHZMcbqqhPArsizlIbSAvDmKbmClkvOa7Uj3-_WbJcJqfEZIw3zyaRwQhrRrjHibLHM6NHkgHNO9FfI99StNpuRWhNtmJfJnIkU8koXT_M90j6iSfk5eeLNmPDFVvfk28cPX28-V7d3n77cXN9WlnOZK4Wid1I5LqWxKBovJQiOyK1FsM4404HpuTPe-0aJ1gFHxkUvWxRegGz25O3l7jEuP1dMWU8hWRxHM-OyJi1Ex3kn2wK-_gscljXO5TcNnHNRK-DynxRroGbASrh70l4oG5eUInp9jGEy8XeB9NmPHvTmR5_9aCZ08VP2Xm3X135C97C1CSnAmw0wyZrRRzPbkB44AQpAicK9v3BYoj0FjDrZcNblQlGXtVvCf175A86UsQQ</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Romero, Lina</creator><creator>Klein, Laura</creator><creator>Ye, Wei</creator><creator>Holmes, Dennis</creator><creator>Soni, Rashida</creator><creator>Silberman, Howard</creator><creator>Lagios, Michael D.</creator><creator>Silverstein, Melvin J.</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast</title><author>Romero, Lina ; Klein, Laura ; Ye, Wei ; Holmes, Dennis ; Soni, Rashida ; Silberman, Howard ; Lagios, Michael D. ; Silverstein, Melvin J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-8e6bd78d477ace63f77164ee4cce1cdada91ab4dafff3865d14e046b75e6f6173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast cancer–specific survival</topic><topic>Breast Neoplasms - mortality</topic><topic>Cancer therapies</topic><topic>Carcinoma in Situ - mortality</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Ductal carcinoma in situ</topic><topic>Fatalities</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Invasive recurrence</topic><topic>Local recurrence</topic><topic>Mammary gland diseases</topic><topic>Mammography</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Probability</topic><topic>Prospective Studies</topic><topic>Radiation therapy</topic><topic>Survival Rate</topic><topic>Therapy</topic><topic>Time Factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romero, Lina</creatorcontrib><creatorcontrib>Klein, Laura</creatorcontrib><creatorcontrib>Ye, Wei</creatorcontrib><creatorcontrib>Holmes, Dennis</creatorcontrib><creatorcontrib>Soni, Rashida</creatorcontrib><creatorcontrib>Silberman, Howard</creatorcontrib><creatorcontrib>Lagios, Michael D.</creatorcontrib><creatorcontrib>Silverstein, Melvin J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romero, Lina</au><au>Klein, Laura</au><au>Ye, Wei</au><au>Holmes, Dennis</au><au>Soni, Rashida</au><au>Silberman, Howard</au><au>Lagios, Michael D.</au><au>Silverstein, Melvin J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>188</volume><issue>4</issue><spage>371</spage><epage>376</epage><pages>371-376</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><coden>AJSUAB</coden><abstract>Local recurrence is used as a marker of treatment failure for patients with ductal carcinoma in situ (DCIS). As follow-up lengthens, distant recurrence, breast cancer–specific survival (BCSS), and overall survival must be monitored. A prospective database was used to analyze 1031 patients with DCIS. Patients having invasive recurrence after DCIS treatment were compared with patients having infiltrating ductal carcinoma (IDC). End points included distant recurrence, BCSS, and overall survival. Overall, patients with DCIS had a BCSS of 99%. BCSS was 85% for patients with invasive recurrences. DDFS in this group was 80%. Stage I IDC patients had a BCSS of 91%, whereas it was 38% in those with stage I IDC and invasive recurrences. Most patients with DCIS that recur can be salvaged. For the small subgroup of patients who recur with invasive breast cancer, survival is similar to that of patients with stage IIA IDC.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15474428</pmid><doi>10.1016/j.amjsurg.2004.06.034</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9610
ispartof The American journal of surgery, 2004-10, Vol.188 (4), p.371-376
issn 0002-9610
1879-1883
language eng
recordid cdi_proquest_miscellaneous_66944975
source ScienceDirect Freedom Collection
subjects Biological and medical sciences
Breast cancer
Breast cancer–specific survival
Breast Neoplasms - mortality
Cancer therapies
Carcinoma in Situ - mortality
Carcinoma, Ductal, Breast - mortality
Ductal carcinoma in situ
Fatalities
Female
Follow-Up Studies
General aspects
Gynecology. Andrology. Obstetrics
Humans
Invasive recurrence
Local recurrence
Mammary gland diseases
Mammography
Medical research
Medical sciences
Mortality
Neoplasm Invasiveness
Neoplasm Recurrence, Local - mortality
Probability
Prospective Studies
Radiation therapy
Survival Rate
Therapy
Time Factors
Tumors
title Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T09%3A59%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20after%20invasive%20recurrence%20in%20patients%20with%20ductal%20carcinoma%20in%20situ%20of%20the%20breast&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Romero,%20Lina&rft.date=2004-10-01&rft.volume=188&rft.issue=4&rft.spage=371&rft.epage=376&rft.pages=371-376&rft.issn=0002-9610&rft.eissn=1879-1883&rft.coden=AJSUAB&rft_id=info:doi/10.1016/j.amjsurg.2004.06.034&rft_dat=%3Cproquest_cross%3E3107829531%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-8e6bd78d477ace63f77164ee4cce1cdada91ab4dafff3865d14e046b75e6f6173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1031201088&rft_id=info:pmid/15474428&rfr_iscdi=true